All News
Kim et al. After first episode VZV in RA or UC treated with JAKi, continued JAKi use does not increase reactivation compared to cessation. @RheumNow #ACR22 Abstr#2220 https://t.co/zx96xgkySU https://t.co/KdniDGCUgI
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abstr#1656 Promising therapy for #lupus. Cenerimod, S1P1 modulator, controls lymphocyte trafficking out of lymph nodes into blood. Phase 2 dose-ranging RCT didn't meet primary endpoint (adjusted for multiple testing) but mSLEDAI-2K reduced in 4mg dose vs PBO @RheumNow https://t.co/YnENTkqClk
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abstr #2194- What is my risk of flare after COVID vaccine?
- Up to 3 wks s/p vaccination, no significant assn w/ risk for flare (aIRR 0.89 95% CI 0.8-.098) including after 1st, 2nd, and 3rd dose
- No significant assn by disease, hx of COVID infxn, vaccine type
@RheumNow #ACR22
Akhil Sood MD AkhilSoodMD ( View Tweet)
Some RA patients do well.
Some do badly, and get frail even before the age of 65 (6% of pts).
These are the ones that get hit by infections with b/tsDMARDs: see below from MarketScan data. These are the patients we need to watch & protect!
ABST2217 @NamrataRheum #ACR22 @RheumNow https://t.co/DXZjFDnCcn
David Liew drdavidliew ( View Tweet)
Nakafero et al. Self-controlled case series analysis. No increased risk RMD flare with SARS-CoV-2 vaccination. In fact reduced risk! aIRR 0.89(0.80-0.98). No evidence in any of multiple subanalyses either @RheumNow #ACR22 Abstr#2194 https://t.co/r5pOkdjnR1 https://t.co/YpwMkJ3WVe
Richard Conway RichardPAConway ( View Tweet)
ACRTIC REWIND finds RA pts w/ sustained clinical remission for at least two years and successfully tapered csDMARDs to half-dose, majority of pts who discontinued csDMARDs remained flare free for 12 months. Abs 2013 #ACR22 @RheumNow https://t.co/HsQz0cJznp https://t.co/QceTXJZiFF
Dr. Rachel Tate uptoTate ( View Tweet)
🌱Plants for joints 🌱
👉16wk
👉whole food plant based diet + Phys activity + stress Mx
👉 metabolic syndrome assoc OA hip/knee
💥 substantial ⬇️ pain + stiffness
💥⬆️ physical function
#ACR22 @RheumNow Abst 1644 https://t.co/u6UufpbrcC
Patricia Harkins DrTrishHarkins ( View Tweet)
Thanks for the love #Philly #ACR22 @RheumNow check out our coverage by logging on to https://t.co/xF1bNhZB1C! https://t.co/ncBM0icZ3c
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Retrospective cohort study 132 immune checkpoint inhibitor arthritis pts Rx with either TNFi ± MTX or IL6Ri ± MTX have a shorter time to cancer progression but faster arthritis control than patients Rx with MTX alone. Bass A Abs#1669 https://t.co/h0Nq6yd2wf #ACR22 @RheumNow https://t.co/XfXMtdbCPB
Dr. Antoni Chan synovialjoints ( View Tweet)
Wallace @BethIWallace et al. Time dependent evaluation GCs and MACE in RA. Effect of steroids in previous 6 months on MACE risk in next 6 months. Odds MACE (vs no steroid) 1.54 (1-7 days) 1.78 (8-90 days) 2.17 (>90 days) @RheumNow #ACR22 Abstr#2219 https://t.co/w4gCgjeSNa https://t.co/TQ9pufGtBD
Richard Conway RichardPAConway ( View Tweet)
Sphygmomanometer for fibromyalgia detection in rheum OPD
🔥⬆️local pain during BP testing strongly indicates presence of FMS
✅useful, easily applicable and practical screening tool
Abst#1225 #ACR22 @RheumNow
Patricia Harkins DrTrishHarkins ( View Tweet)
#FMF 2350 pts = 40% with arthritis
- Colchicine resistance in 20%
- M694V mutation carrier rate high (mutant MEFV gene)
- FMF pts with arthritis have a more severe disease course
- incidence of spondyloarthropathy was increased in FMF
#ACR22 @RheumNow abst#1830 https://t.co/uiLhjK0UjY
Bella Mehta bella_mehta ( View Tweet)
Rohmer @TerrierBen et al. 196 cases of PAN from France. 28% assoc another condition - MDS and cancer mainly. Relapse in 39% - assoc age>65, GI, skin necrosis. Death assoc age>65, AKI, secondary PAN, necrotic purpura. @RheumNow #ACR22 Abstr#2232 https://t.co/fyJY9O3Gm7
Richard Conway RichardPAConway ( View Tweet)
Tonight! Join our RA Topic Panel with panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan
@RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan #ACR22
https://t.co/j13W4GM56w https://t.co/fgDwPVdskC
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
Richard Conway RichardPAConway ( View Tweet)
Abstr #2192 risk of serious infxn in newborns of mothers on TNFi by placental transfer
- % serious infection in TNFi in high vs low placental transfer (2.1% vs 1.6%)
- HR (high vs low) 0.98 (95% CI 0.36-2.61)
- No significant difference in risk of serious infxn
@RheumNow #ACR22 https://t.co/7Lfpf7PERu
Akhil Sood MD AkhilSoodMD ( View Tweet)
Which patients with IIM are high risk for #cancer?
Abstract #0002 #ACR22 @RheumNow #ACRBest
📍Dermatomyositis
📍Anti-TIF-gamma, anti-NXP2
📍Age > 40y at dz onset
📍Dysphagia
📍Cutaneous necrosis
📍Persistent high dz despite immunosuppressive tx
Catherine Sims, MD DrCassySims ( View Tweet)
Which is better for CV risk in RA:
triple therapy DMARDs or TNFi?
TARGET study
n=159 using PET/CT surrogate (endpoint responsiveness👀)
- either led to benefit
- both equally good
- benefit *not* linked to change in DAS28
A direct CV effect of RA Rx?
ABST2215 #ACR22 @RheumNow https://t.co/4FPvSbfGsD
David Liew drdavidliew ( View Tweet)
Vaccination +/- prior Covid-19, and with either mRNA or vectored DNA vaccines were not associated with AIRD flares. Negative association 21-days after 1st Covid-19 vaccination and no association after 2nd or 3rd doses. Nakafero G Abs#2194 https://t.co/vA8cMNQGkr #ACR22 @RheumNow https://t.co/SZnXejnmYt
Dr. Antoni Chan synovialjoints ( View Tweet)